ERBB2 and breast cancer: To further explore the predictive value of the HER2DX pCR likelihood score when patients are treated with neoadjuvant anti-HER2-based therapy, we interrogated the CALGB-40601 and ISPY-2 publicly available breast cancer datasets, which include gene expression data and pathological response data.